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Abstract
Bipolar disorder (BD) is a multi-factorial disorder caused by genetic and environmental influences. It has a large
genetic component, with heritability estimated between 59-93%. Recent genome-wide association studies (GWAS)
using large BD patient populations have identified a number of genes with strong statistical evidence for
association with susceptibility for BD. Among the most significant and replicated genes is ankyrin 3 (ANK3), a large
gene that encodes multiple isoforms of the ankyrin G protein. This article reviews the current evidence for genetic
association of ANK3 with BD, followed by a comprehensive overview of the known biology of the ankyrin G protein,
focusing on its neural functions and their potential relevance to BD. Ankyrin G is a scaffold protein that is known to
have many essential functions in the brain, although the mechanism by which it contributes to BD is unknown.
These functions include organizational roles for subcellular domains in neurons including the axon initial segment
and nodes of Ranvier, through which ankyrin G orchestrates the localization of key ion channels and GABAergic
presynaptic terminals, as well as creating a diffusion barrier that limits transport into the axon and helps define
axo-dendritic polarity. Ankyrin G is postulated to have similar structural and organizational roles at synaptic
terminals. Finally, ankyrin G is implicated in both neurogenesis and neuroprotection. ANK3 and other BD risk genes
participate in some of the same biological pathways and neural processes that highlight several mechanisms by
which they may contribute to BD pathophysiology. Biological investigation in cellular and animal model systems
will be critical for elucidating the mechanism through which ANK3 confers risk of BD. This knowledge is expected
to lead to a better understanding of the brain abnormalities contributing to BD symptoms, and to potentially
identify new targets for treatment and intervention approaches.
Keywords: Ankyrin G, Bipolar disorder, Schizophrenia, Genome-wide association study, GWAS, Axon initial segment,
Nodes of Ranvier, GABA, Neurogenesis, Synapse
Review
Bipolar disorder (BD) is a debilitating illness for which the
pathogenesis is poorly understood. BD is defined by alter-
nating episodes of mania and depression. Manic symp-
toms include impulsivity, high-risk behavior, increased
pleasure seeking (hedonia), and decreased sleep, whereas
depressive symptoms include anhedonia, impaired cogni-
tion, and suicidality [1].
While the biology of bipolar disorder is not well under-
stood, there is a convergence of evidence reviewed else-
where [2-4] implicating heightened pro-inflammatory
processes, specifically increased cytokine production, as
well as dysfunction of the hypothalamic–pituitary–adrenal
axis, as indexed by enhanced cortisol secretion after dexa-
methasone or corticotropin releasing hormone challenge.
The most consistently reported brain abnormalities in BD
include enlarged lateral ventricles and white matter abnor-
malities, particularly in prefrontal regions. Albeit less con-
sistent, structural imaging studies have found reduced
hippocampal volume in BD that is more pronounced in
adolescents than adults, possibly due to long-term medi-
cation effects, and larger amygdala volume in adults [5].
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reduced levels in the dorsolateral prefrontal cortex, an-
terior cingulate, and hippocampus of individuals diag-
nosed with BD. Functional neuroimaging studies
suggest that activity of limbic regions (hippocampus,
amygdala) is increased during emotional processing tasks,
while frontocortical activity is decreased during cognitive
and emotional tasks.
A number of cellular mechanisms have been impli-
cated in BD pathophysiology and are reviewed in greater
detail elsewhere [6]. Of relevance to this article, calcium
signaling, which controls many brain essential functions
(e.g., neurotransmitter release), appears to be dysregu-
lated in BD based on elevated intracellular calcium con-
centration in platelets, lymphocytes, and transformed
lymphoblasts from patients. A number of intracellular
signaling cascades (e.g., brain-derived neurotrophic fac-
tor [BDNF] signaling) appear to be perturbed in BD and
have been linked to altered glutamatergic neurotrans-
mission, as suggested by altered glutamate levels in
plasma, serum, and cerebrospinal fluid from patients,
which in turn may impair synaptic plasticity. Mood sta-
bilizers reverse many of the changes described above,
providing support for the relevance of these changes to
disease. Likewise, the mechanisms of action of BD medi-
cations suggest cell biological processes that may be
altered in BD [reviewed by [7]]. Lithium has been used
for BD treatment for over 60 years, and as such has been
extensively studied both clinically and preclinically. Lith-
ium inhibits several enzymes including inositol monopho-
sphatase (IMPase) within the phosphoinositol pathway
that mediates many activities, notably cell proliferation
and survival [8], as well as glycogen synthase kinase
(GSK3) [9] that has a multitude of substrates involved in
various cellular processes including cell growth and sur-
vival, axonal growth and guidance, synaptogenesis, and
neurogenesis [10]. Lithium, as well as the mood stabilizers
valproate and carbamazepine, are documented to have
neurotrophic and neuroprotective properties, as suggested
by larger brain regional volumes in treated BD patients,
and upregulation of BDNF and the neuroprotective mol-
ecule B-cell lymphoma/leukemia-2 (Bcl-2) in rodent brain.
Of note, there is solid evidence that, like antidepressant
medications, some mood stabilizers increase adult neuro-
genesis in rodents in the hippocampus, one of two regions
in the mature brain where new neurons are generated
[11], suggesting a putative role of adult-born neurons in
neural processes underlying BD.
BD has a large genetic component, with increased risk
in families of affected individuals, and heritability esti-
mated between 59-93% based on several twin studies
[11-15]. In addition, many of the physiological and
neural abnormalities discussed above that occur in indi-
viduals with BD are also found at higher frequency in
unaffected relatives [16], further supporting a genetic
basis to this disorder. Given the substantial contribution
of genetic factors to BD, identifying the susceptibility
genes will unquestionably improve knowledge of the
neurobiological underpinnings, which in turn may point
to new targets for the development of more effective
treatments. However, gene discovery has been extremely
difficult, with genetic linkage and association studies
fraught with weak and inconsistent results [1,17]. The
reasons are many, but primarily small subject samples
with low statistical power and a lack of methods to
screen genes in a manner unbiased by prior potentially
incorrect hypotheses [18]. As reviewed below, recent
genome-wide association studies (GWAS) of large sub-
ject samples and meta-analyses across multiple studies
have been revolutionary in identifying several genes with
highly significant and replicated statistical evidence for
association with BD. Future GWAS of new subject sam-
ples and meta-analyses of the results with existing data
will provide increased statistical power to identify add-
itional genes, likely emerging from those falling just
below genome-wide significance in current analyses [19].
With compelling candidate risk genes now at hand and
others anticipated in the near future, we are entering an
era of functional studies to delineate their roles in the
normal and diseased brain [20]. Expectations are high
that GWAS will lead to major advances in understand-
ing the neurobiological basis of BD. A 2010 Nature edi-
torial entitled “A Decade for Psychiatric Genetics”,
highlighted GWAS as one of the new technologies “that
are ushering in an era in which the neural circuitry
underlying cognitive dysfunctions, for example, will be
delineated” [21].
Genome-wide association studies identify Ankyrin 3 as a
bipolar disorder risk gene
GWAS serve as an unbiased approach to identify disease
risk genes and pathways in order to understand the
underlying molecular and cellular pathophysiology.
GWAS test millions of single nucleotide polymorphisms
(SNPs) across the genome for differences in frequencies
of SNP alleles between case and control subjects. The
results require stringent correction for the enormous
number of tests, with the genome-wide significance
threshold typically set at p < 5×10
-8 [22]. Sample sizes
in the thousands are required to obtain sufficient statis-
tical power to surpass this significance threshold given
the modest effect of any one gene on disease risk. This
has been achievable because of collaboration between
many research groups contributing DNA samples and/or
genotype data into a combined genetic analysis, or for
replication of primary findings to obtain imperative sup-
port from independent samples that increases confi-
dence in the results.
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genome-wide significance threshold of p<5×10
-8 in a
BD GWAS was diacylglycerol kinase eta (DGKH) [23],
which has been supported by subsequent studies [24].
This association was particularly appealing since DGKH
is involved in phosphoinositol signaling through which
lithium may mediate its clinical effect [25]. Soon after, a
2009 meta-analysis of three GWAS totaling nearly 4,400
cases and over 6,200 controls identified the ankyrin 3
(ANK3) gene with association evidence surpassing the
genome-wide significance threshold, and the voltage-
gated calcium channel subunit 1c (CACNA1C) gene just
below the threshold (p = 7.0 × 10
-8) [26]. Subsequent
GWAS and targeted association studies have supported
the ANK3 association, which spans a 250 kilobase region
at the 5’ end of the gene (Figure 1; most significant SNPs
rs10994336 and rs1938526), as well as indicated a sec-
ond independent association signal in a 70 kilobase re-
gion at the 3’ end (rs9804190) [27-32]. Although several
studies used some of the same cases, which may inflate
the importance of the ANK3 results, a meta-analysis of
three of these studies reported evidence well above
genome-wide significance after removing overlapping
subjects (p=1.1 × 10
-10) [30]. Some GWAS and targeted
studies of ANK3 have failed to detect significant associ-
ation surviving multiple test correction with BD risk, age
at onset, or psychiatric symptoms, or with risk of other
disorders including schizophrenia, major depressive dis-
order, and attention deficit hyperactivity disorder [24,33-38].
However, many of these studies utilized samples that
lacked statistical power to detect small genetic effects
such as that of ANK3. Subsequent targeted studies also
support CACNA1C association with BD, as well as
schizophrenia and major depressive disorder [39-43],
suggesting at least partially overlapping genetic etio-
logy across major mental illness, as also proposed by
other studies [44]. Two BD GWAS published in 2011
also reported novel genome-wide significant associations
with neurocan (NCAN), an extracellular matrix protein
involved in neural adhesion and neurite growth [45], lectin
mannose-binding 2-like (LMAN2L) implicated in protein
export from the endoplasmic reticulum, the adjacent
genes doublecortin-like kinase 3 (DCLK3) and tetratrico-
peptide repeat and ankyrin repeat containing 1
(TRANK1), the prostaglandin F receptor gene (PTGFR),
and a region on chromosome 3p21.2 containing several
genes [27,46].
The Psychiatric GWAS Consortium Bipolar Disorder
Working Group (PGC-BD) recently published the lar-
gest meta-analysis of BD GWAS to date [47]. The pri-
mary analysis of 7,481 cases and 9,250 controls from 11
previously published GWAS, some of which are men-
tioned above, identified two SNPs surpassing the genome-
wide significance threshold. The top SNP (rs10994397,
p=7.1×10
-9)i sw i t h i nt h e5 ’ region of ANK3 that was
previously reported, and the other SNP (rs9371601,
p=4.3×10
-8) is located in the SYNE1 gene.S Y N E 1has
an alternative splice form called CPG2 that functions
in postsynaptic recycling of glutamate receptors [48],
and has been subsequently associated with major de-
pression [49]. When combining the primary dataset and a
replication sample of 4,496 cases and 42,422 controls, both
of these results fell just below genome-wide significance.
However, two other genes emerged, the previously
reported CACNA1C (rs4765913, p=1.52×10
-8)a n dODZ4
(rs12576775, p=4.4×10
-8), which encodes a member
of the tenascin cell surface proteins implicated in neu-
ronal pathfinding [50]. The PGC Bipolar Disorder and
Schizophrenia Working Groups also performed a joint
GWAS of their primary samples, totaling 16,374 cases and
14,044 controls. Genome-wide significant associations with
BD and schizophrenia were detected for three previously
reported loci, notably the 5’ region of ANK3 (rs10994359),
CACNA1C (rs4765913 and rs4765905), and the chr3p21.3
locus (rs736408 and rs2239547), suggesting they are shared
risk factors between BD and schizophrenia.
Figure 1 Human ANK3 gene and protein structure. The ANK3 gene has many transcript isoforms (bottom) as a result of extensive alternative
splicing of unique 5’ exons containing transcription start sites with up to 43 other exons (exons indicated by vertical bars, introns by horizontal
lines). Ankyrin G protein domains (blue bars) are shown above the gene structure. SNPs with evidence for disease association surpassing the
genome-wide significance threshold in one or more GWAS of BD or a joint analysis of BD and schizophrenia are indicated at top (red vertical
lines). Red bars indicate regions in linkage disequilibrium with the identified SNPs within which the functional sequence variants contributing to
disease risk are likely located (5’ associated region on right, 3’ associated region on left). Image adapted from the UCSC Genome Browser.
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First, as statistical evidence for a particular SNP can fluc-
tuate between samples, genes may rise above or drop
below the genome-wide significance threshold in differ-
ent analyses. It is possible that genes falling below the
threshold in a particular analysis are legitimate risk
genes, which data from additional samples may help re-
solve, and that many more genes will be identified in fu-
ture studies. Second, the genome-wide significant SNPs
identified to date have very small effects on disease, with
odds ratios under 1.2 on average [23,46,47], indicating
an only slightly increased risk of disease for carriers of
the SNP allele that is associated with BD compared to
non-carriers. It is possible, though, that the contribution
to variation in brain processes underlying BD is much
larger than for disease risk per se. Regardless of the
effect size, the genes suggest mechanisms that provide
new insight of the neurobiology of BD, and may also
reveal new therapeutic targets.
To begin to elucidate the role of ANK3 in BD, the SNPs
identified by GWAS have been examined in relation to
brain processes and neuroanatomical abnormalities often
linked to BD, as well as for association with other psychi-
atric disorders. It should be noted that the ANK3 SNPs
have no apparent function, but regardless they serve as
markers of the true genetic variants contributing to disease
that might be located nearby in the gene. In studies com-
paring individuals carrying the SNP risk alleles with non-
carriers, ANK3 has been associated with predisposition to
anhedonia, altered novelty seeking, impaired threat/stress
signal processing, poorer cognition (sustained attention, be-
havioral flexibility, and working memory), and reduced in-
tegrity of white matter tracts [51-55]. These data provide
evidence that sequence variation in ANK3 contributes to
functional and structural changes in the brain that may be
related to risk for BD. In addition, ANK3 expression is
reported to be lower in superior temporal gyrus of schizo-
phrenia subjects [54], suggesting that ANK3 downregula-
tion may underlie psychopathology. Given the extent of
this evidence for ANK3 impacting brain function, investi-
gating the neural circuits and processes that it regulates is
fundamentally important to understanding the abnormal-
ities underlying BD and perhaps other mental illnesses.
ANK3 has essential functions in brain: possible relevance
to BD
1) The ankyrin gene family:
Ankyrins are a family of membrane skeletal proteins. In
mammals, there are 3 ankyrin family members: ANK1
(encoding ankyrin R), ANK2 (ankyrin B), and ANK3
(ankyrin G). ANK1 is predominantly expressed in ery-
throcytes, striated muscle, and some central nervous sys-
tem (CNS) neurons [56]. ANK2 is mainly expressed in
brain, striated muscle, kidney, thymus, and peripheral
blood cells [57]. ANK3 is expressed in nearly all tissues,
including brain [58-61].
2) General function and tissue expression of ANK3:
The ankyrin G protein encoded by ANK3 has a general
role in multiple tissues as a scaffold protein and adapter
molecule between various integral membrane proteins
and the spectrin cytoskeleton, forming protein com-
plexes that participate in organizing complex microdo-
mains with both extracellular and intracellular functions
[For review, see [62,63]]. Ankyrin G is widely expressed
throughout the body, including but not limited to heart,
skeletal muscle, kidney, erythrocytes, epithelial cells, and
brain. In the human brain, ANK3 is most highly
expressed in the frontal cortex, cingulate cortex, hippo-
campus, thalamus, and cerebellum [64,65]. Importantly,
several of these regions are within neural circuits impli-
cated in mood and cognition, processes that are altered
in BD.
The function of a gene of interest is typically charac-
terized using transgenic mice in which expression of the
gene is increased (i.e., overexpressed) or reduced (i.e.,
knocked out). In the case of a psychiatric disorder such
as BD, examining the behavior of transgenic models may
provide insight into relevant neural circuits within which
the gene functions. Only one transgenic model of the
mouse Ank3 gene has been reported to date, in which
brain-specific Ank3 isoforms are exclusively disrupted,
while more widely-expressed isoforms are unchanged
[66]. The initial characterization of Ank3−/− mice that
completely lack brain-specific isoforms noted a progres-
sive early-onset ataxia due to impaired action potential
firing at axon initial segments (AIS) of Purkinje neurons
in the cerebellum, which is important for motor control
[66]. We have found that Ank3+/− mice with one func-
tional copy exhibit altered mood-related behaviors and
elevated stress reactivity, without any detectable motor
deficits as in null Ank3−/− mice. Interestingly, we have
found that ankyrin G suppression using viral-mediated
RNA interference leads to a highly similar phenotype that
can be reversed by chronic lithium treatment, lending cre-
dence to the relevance of the behavioral changes to BD
(Leussis et al., in press).
3)ANK3 gene and protein structure:
The ANK3 gene is located within a 700 kilobase region
on human chromosome 10 (Figure 1). ANK3 has several
5’ leading exons containing transcription start sites that
are alternatively spliced with 43 downstream exons to
generate many transcript variants ranging from 4–15
kilobases in size [59,60]. The functional significance of
these unique 5’ exons is not understood, although exon
1b is known to drive transcription of transcript variants
that are exclusively expressed in brain, whereas transcripts
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In relation to the BD association signals, the 5’ associated
region spans exon 1b, and is adjacent to an alternative 5’
exon, exon 1e [26]. The 3’ associated region spans many
exons encoding the spectrin-binding and death domains
of the ankyrin G protein product [29] (described below).
There is a common molecular organization shared at
the protein level across the three ankyrin genes. The
N-terminal domain consists of 24 Ank repeats, a
known protein binding motif that binds numerous
membrane or cytoplasmic proteins [60,67]. These Ank
repeats consist of a 33 amino acid structural motif [68].
Following the N-terminal Ank repeats is a spectrin-
b i n d i n gd o m a i nt h a ta l l o w sa n k y r i nt ol i n kt ot h ec y t o -
skeleton [69]. The binding affinity of both the N-
terminal Ank repeats and the spectrin-binding domain
is modulated by the C-terminal regulatory region. The
very large brain ankyrin isoforms (440 kilodalton [kDa]
ankyrin B and 480 kDa ankyrin G) include an extended
tail inserted between the spectrin-binding domain and
the C-terminal regulatory domain, and are predicted to
take an extended random coil shape [59]. Alternative
splice variants of the tail domain also give rise to add-
itional isoforms [59]. The function of the tail domain is
not yet clear, but it is postulated to play a role in intra-
molecular interactions with the membrane binding do-
main that regulate functional interactions [70]. The 480
and 270 kDa isoforms of ankyrin G contain a serine
rich domain C-terminal to the spectrin binding domain
that appears to be required to restrict them to the axon
initial segment (AIS) [71]. While these domains are
recognized as functional elements of the ankyrin G
protein, several studies have shown the existence of
several isoforms of the protein that lack one or more of
these domains. Alterations of the domain structure are
thought to modulate activity of the protein as described
below.
Several large isoforms of ankyrin G have been identi-
fied and are the predominant isoforms associated with
neuronal function and development. The 440 kDa,
270 kDa (lacks exon 37) and 190 kDa (lacks the serine
rich and tail domains) isoforms have been shown to be
expressed in neurons [71]. These isoforms are most
often associated with the AIS and Nodes of Ranvier, and
are required for the organization of these membrane
domains. As described below, several studies have sug-
gested lower molecular weight isoforms of ankyrin G
lacking most of the membrane binding domain localize
to other subcellular compartments. For example, two
studies demonstrated that the 100 kDa and 120 kDa iso-
forms present in mouse macrophages or expressed in
3T3 or COS-1 cells localize to late endosomes and lyso-
somes involved in protein degradation [72,73].
Furthermore, a 116 kDa (AnkG119) isoform present in
kidney and muscle associates with the Golgi apparatus
that packages proteins for secretion or transport within
the cell [58].
4) Neural functions of ANK3.
Synaptic organization and stabilization
Ankyrin G has been implicated in synaptic function
(Figure 2A), although the majority of evidence is from
studies of the neuromuscular junction (NMJ) in the per-
ipheral nervous system of the fruit fly (Drosophila). In
Drosophila, the presynaptic NMJ is stabilized by giant
isoforms of brain-specific Ank2 (Ank2-L), which appear
homologous to mammalian ankyrin G large isoforms.
These directly bind and organize synaptic microtubules,
thus contributing to stability of the presynaptic terminals
[74]. Mutations of Ank2-L have been shown to signifi-
cantly affect NMJ stability in Drosophila larva, as evi-
denced by disintegration of the synaptic cytoskeleton
that results in disassembly of presynaptic active zones,
withdrawal of synaptic boutons, and reduced terminal
size [75]. At the Drosophila postsynaptic NMJ, synapse
development is dependent on spectrin, which ankyrin
directly interacts with, but is also mediated by Ank2-L
isoforms [76].
There is also evidence that ankyrin G may function in
mammalian synapses. For example, ankyrin G has been
identified as a component of the postsynaptic density in
mouse brain [77,78]. Further, treatment with the mood
stabilizer lithium significantly increased ankyrin G levels
in the postsynaptic density in rat hippocampus, while
valproic acid treatment had a more modest effect on in-
creasing ankyrin G expression [78].
Synaptic defects and reduced synaptic plasticity have
been increasingly linked to BD and other psychiatric dis-
eases in both humans and animal models [79,80]. Further,
mood stabilizers such as lithium affect the levels of certain
synaptic proteins [78,81] and increase long term potenti-
ation (LTP), which is representative of increased neural
plasticity [82]. A role of ankyrin G at the synapse, which
we postulate occurs in mammals as it has been shown in
Drosophila, could represent one cellular mechanism of
decreased synaptic plasticity that may underlie BD.
Cellular trafficking and intracellular signaling
It is postulated that certain isoforms of ankyrin G that
lack both the membrane-binding and spectrin-binding
domains are associated with Golgi, late endosomes, lyso-
somes, and the sarcoplasmic reticulum (Figure 2B) that
mediate transport and storage of proteins and molecules
within cells. For example, in kidney cells, the 116 kDa
isoform of ankyrin G localizes with Golgi and endo-
somes where it is postulated to play a role in organizing
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contribute to the localization of cell adhesion molecules, synaptic receptors, or other synaptic scaffold proteins, as well as to the overall stability
of the synapse. (B) Some isoforms of ankyrin G localize to late endosomes and lysosomes where they function in cellular trafficking, thereby
directing specific proteins to different subcellular regions. In neurons, cellular trafficking occurs at the pre- and post-synapse of neurons, as well as
within the cell body as depicted. (C) Ankyrin G contributes to cellular compartmentalization, helping to distinguish axonal from dendritic
processes through the establishment of an axonal barrier at the axon initial segment (AIS) that prevents transport of non-axonal cargo proteins
into the axon. (D) Ankyrin G serves as a key scaffold protein at the AIS, interacting with cytoskeletal proteins such as spectrin and actin to localize
voltage-gated sodium and potassium channels, cell adhesion molecules (e.g. neurofascin), and GABAergic inhibitory postsynaptic terminals to this
region. (E) Similar to its role at the AIS, ankyrin G localizes voltage-gated sodium and potassium channels and cell adhesion molecules to the
Nodes of Ranvier, which is mediated through reciprocal interactions with myelin-generating glial cells.
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polarized vesicles [58,83]. Further, ankyrin G interacts
with Hook1, a protein presumed to function in traffick-
ing of proteins to late endosomes [84]. Smaller isoforms
of ankyrin G (100, 120 kDa) have also been associated
with late endosomes and lysosomes in macrophages
[72]. The putative function of these smaller isoforms in
trafficking membrane-bound proteins within the cell is
as likely to occur in neurons as in other cell types. In
fact, endosomal trafficking is essential for neuronal func-
tion by targeting proteins to the correct compartments
to maintain axo-dendritic polarity, discussed above, and
by regulating presynaptic vesicle recycling as well as sur-
face expression and internalization of postsynaptic
receptors [85,86].
Ankyrin G is implicated in cellular signaling cascades
that mediate a diversity of cellular processes. For example,
the small 110 and 120 kDa isoforms in late endosomes and
lysosomes have been shown to contribute to lysosome-
mediated downregulation of receptors by binding directly
to the p85 subunit of phosphatidylinositol 3’-kinase (PI3K).
This interaction modulates degradation of the platelet-
derived growth factor receptor (PDGFR) that activates
different downstream signaling cascades, including the
PI3K-Akt and the Ras-MAPK pathways that mediate
cellular processes including proliferation and survival
[73]. Interestingly, the phosphoinositol pathway is a
putative target of lithium and valproate [25,87-89],
highlighting a potential overlap between the cellular
functions of ANK3 with BD treatment response.
Establishment and maintenance of axo-dendritic polarity
The distinction between dendrites and axons is critical
to neuronal function, yet the mechanisms underlying the
differentiation of these two compartments are just being
identified. Ankyrin G contributes to the maintenance of
axo-dendritic polarity of neurons by forming a critical
part of the diffusion barrier that assembles in the AIS
within 48 hours of axon-dendrite differentiation and acts
as a selective filter for axonal transport and diffusion
(Figure 2C). When ankyrin G expression is perturbed,
the axonal barrier is disrupted and proteins that were
not previously detected in the axon are readily observed
[90,91]. Additionally, in the absence of ankyrin G, axons
lose their identity and gain both structural and molecu-
lar characteristics of dendrites, including spine-like pro-
trusions that contain numerous markers for postsynaptic
densities, and appear to form synapses, further support-
ing a role for ankyrin G in regulating axon-defining
properties both in vitro and in vivo [90,92]. Consistent
with this function, interactions between ankyrin G and
the cell surface protein neuroglian mediate axonal and
dendritic morphogenesis, such as the establishment of
large dendritic arbors, at least for certain neuronal sub-
types in Drosophila embryos [93].
Perturbed axo-dendritic polarity could be related to
the mechanism of ankyrin G in BD. For neurons to
function optimally within neural circuits, they require
proper establishment of both axonal and dendritic pro-
cesses. Interfering in this process, as could occur in indi-
viduals with altered levels of functional ankyrin G,
would have wide-ranging implications for brain func-
tion. This could include alterations in neural circuits
involved in mood regulation and cognition that are
impaired in BD.
Formation and maintenance of the axon initial segment
and Nodes of Ranvier
The best-characterized function of ankyrin G in the
brain occurs at the AIS and Nodes of Ranvier (NoR) of
neurons (Figure 2D, E), where action potentials are gen-
erated and propagated down the axon to presynaptic
terminals. Ankyrin G is considered a master organizer of
the AIS, based on evidence that other AIS-associated
proteins, including ΒIV-spectrin, neurofascin-186, and
ion channels (especially voltage-gated sodium and potas-
sium channels), depend on the presence of ankyrin G to
form localized clusters at the AIS [66,67,94-100]. Fur-
ther, in hippocampal neuronal cultures, ankyrin G is
required for the maturation of the cisternal organelle
that functions in regulating calcium levels at the AIS
[101]. Recent data from Galiano et al. [102] suggest that
ankyrin G is established at the AIS through exclusion of
ankyrin G from the distal axon by an ankyrin B cytoskel-
eton. Subsequent organization of the AIS is orchestrated
through multiple ankyrin G protein domains including
the membrane-binding, spectrin-binding, and tail domains
[71]. Ankyrin G appears to function in this role from early
in development through adulthood, suggesting a role in
formation and maintenance of the AIS [95]. The disrup-
tion of the AIS in knockout mice lacking brain-specific
isoforms of ankyrin G correlates with deficits in the
initiation of action potentials and decreased repetitive
firing in cerebellar Purkinje cell neurons [66]. Recent
findings point to a mechanistic role for B-catenin and
G S K 3 - a l p h a / b e t aa tt h eA I S ,w h e r et h e yc o n t r i b u t et o
the control of sodium channel density, and hence
neuronal excitability [103]. This is interesting given
that GSK3 is a known target of lithium [9], suggesting
a potential AIS-related mechanism by which lithium
may mediate its clinical effect on BD symptoms.
While these studies provide evidence for an essential
contribution of ankyrin G to neuronal function, it may
also contribute to more dynamic aspects of neuronal
homeostatic plasticity. Two studies, one examining rat
hippocampal neurons and the other using chick auditory
neurons, demonstrated that altered neuronal activity led
Leussis et al. Biology of Mood & Anxiety Disorders 2012, 2:18 Page 7 of 13
http://www.biolmoodanxietydisord.com/content/2/1/18to changes in the position or length of the AIS, which in
turn led to changes in neuronal excitability [104,105].
Such changes could be important to both developmental
refinement and function of mature neuronal circuits.
While it is clear that ankyrin G plays a critical role in
recruiting and maintaining ion channels at the AIS and
NoR, there is also some evidence that ankyrin G plays a
modulatory role in the opening or closing of some of
these channels. For example, ankyrin G, but not ankyrin B,
regulates the inactivation gating of the sodium channel
Nav1.6 in cells expressing the human variant of this chan-
nel, an effect that is likely mediated by the membrane-
binding domain of ankyrin G [106]. Although this effect
has only been demonstrated for a single channel type, it is
reasonable to postulate that other channels may be simi-
larly modulated by ankyrin G. Altering channel properties
can affect neural circuit performance on many levels, thus
providing another plausible mechanism through which
alterations in ankyrin G levels or function could impact
neural circuits involved in BD.
The localization of ankyrin G to NoR is dependent on
interaction with glial cells (Figure 2E). Current data suggest
that soluble factors secreted by glial cells in both the per-
ipheral and central nervous systems recruit neurofascin-
186 (NF-186), which in turn recruits ankyrin G to NoR
[107-109]. Glial cells mediate interactions between
ankyrin G and the cytoskeleton, thus initiating subse-
quent recruitment and stabilization of sodium and po-
tassium channels, which are required for saltatory
conduction of action potentials along myelinated axons
(for review, see [110]).
Alterations in AIS and NoR formation and mainten-
ance, which ultimately affect action potential firing and
propagation, have clear implications for proper develop-
ment and function of neural circuits that may be related
to the role of ANK3 in susceptibility to BD. As evi-
denced by the ataxia exhibited by knockout mice lacking
brain-specific (exon 1b-derived) isoforms of the mouse
Ank3 gene (Ank3−/− mice) [66], decreased ankyrin G
expression affects neuronal performance to a degree that
alters functional output, at least in neural circuits spe-
cific to motor control and movement. It is likely that
similar deficits, although perhaps less obvious, also
occur in other circuits relevant to BD where ankyrin G
is expressed. In fact, our research demonstrating altered
mood-related behaviors in mice with ankyrin G suppres-
sion in the dentate gyrus via RNA interference (Leussis
et al., in press) implies that other neural circuits includ-
ing dentate gyrus are functionally affected by perturbed
ankyrin G expression.
Similar to its role in localizing proteins such as ion
channels and cell adhesion molecules to the AIS, ankyrin
G also directs the localization of inhibitory GABAergic
interneuron presynaptic terminals onto the AIS of
excitatory neurons (Figure 2D). GABAergic inhibitory
activity at the AIS has a critical role in modulating the
firing of excitatory neurons in multiple brain regions in-
cluding the cortex, hippocampus and cerebellum. Con-
ventional knockout of Ank3 brain-specific isoforms in
mice results in disruptions of neurofascin gradients at
the AIS of cerebellar Purkinje cells. As a result,
GABAergic pinceau synapses from interneurons, which
normally localize to the AIS according to the neurofas-
cin gradient, are instead broadly distributed across the
axonal and soma membranes, resulting in a disruption
of the GABAergic inhibition near the AIS in these mice
[111,112]. A similar observation is made for excitatory
cortical neurons, which also receive inhibitory inputs
from GABAergic interneurons, and are similarly
dependent on the presence of ankyrin G for proper
localization and distribution of GABAergic terminals at
the AIS [113,114]. For a detailed review of the postulated
mechanisms underlying this phenomena, see Huang
[115].
Although there is no direct evidence for how or if
alterations in GABAergic inhibition contribute to BD
pathophysiology, several changes in the GABAergic sys-
tem have been reported in individuals with BD. These
include decreased GABA(B) receptors in lateral cerebella
[116], and decreased parvalbumin and somatostatin-
expressing GABAergic interneurons in the dorsolateral
prefrontal cortex [117]. Further, mood stabilizers alter
the epigenetic regulation of GABAergic targets, revers-
ing GABAergic gene promoter region hypermethyla-
tion that is thought to produce decreased expression
of multiple GABAergic targets in BD [118,119]. Thus,
the role of ankyrin G in mediating the localization of
GABAergic synapses to the AIS could further exacer-
bate GABAergic dysfunction in BD, as a decrease in
GABAergic input would be compounded by improper
targeting of inhibitory axon terminals onto excitatory
neurons.
Neurogenesis and neuroprotective functions
A recent study demonstrated that ankyrin G is required
for generation of new neurons (neurogenesis) in the sub-
ventricular zone of the adult rodent brain [120]. Ankyrin
G is essential for assembly of the subventricular zone
niche through lateral adhesion of progenitor cells, which
serves as a matrix upon which new neurons are gener-
ated. In the absence of ankyrin G, niche assembly does
not occur and neurogenesis is substantially reduced or
absent. Although this report focused exclusively on
neurogenesis in the subventricular/subependymal zone,
it is possible that ankyrin G has a similar role in the sub-
granular zone of the hippocampal dentate gyrus, the
other site of neurogenesis in the mature brain.
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adulthood has been linked to mood disorders such as
depression and anxiety, as well as to antidepressant re-
sponse [For review, see [121,122]]. Further, several mood
stabilizers (lithium, valproate, carbamazepine, and lamo-
trigine) are known to modulate adult neurogenesis in
dentate gyrus [11,123], highlighting a putative thera-
peutic mechanism for these medications. Although few
direct links between BD and neurogenesis have been
reported, decreased hippocampal volume and altered
hippocampal function do occur in BD [5,124] and could
result, at least in part, from decreased neurogenesis.
Ankyrin G also plays a protective role in mediating
brain immune responses, according to studies in both
human and mouse translational models. Specifically,
individuals with Alzheimer’s disease that also express
high levels of ankyrin G in frontal cortex and elevated
levels of ankyrin G antibodies in serum exhibit signifi-
cantly reduced cognitive decline than individuals with
significantly lower ankyrin G serum antibody levels
[125]. Further, two different mouse translational models
of Alzheimer’s disease that exhibit beta-amyloid accumu-
lation improve following innoculation with ankyrin G
antibody, showing reduced brain beta-amyloid pathology
[125]. Although this is the first reported occurrence of
neuroprotective effects of ankyrin G for a specific brain
pathology, it is reasonable to expect that ankyrin G may
also act in a neuroprotective fashion in other disease
instances in the brain.
Putative common pathways of ANK3 and other risk genes
in BD pathophysiology
Based on the known functions of ANK3, and those of
other BD risk genes identified by GWAS discussed above,
one can speculate on common pathways underlying these
genes that may be related to their mechanism in BD.
These pathways are particularly worthy of functional stud-
ies in cellular and animal models to delineate the potential
role of ANK3 and other risk genes in BD pathophysiology.
The CACNA1C gene encodes the pore-forming alpha
1C subunit of the voltage-gated calcium channel, which
is important in mediating neuronal excitability via cal-
cium influx in response to neuronal activity. As ankyrin G
is involved in maturation of the cisternal organelle that
regulates calcium levels at the AIS [101], both CACNA1C
and ANK3 appear to function in calcium-mediated neur-
onal excitability. Further, an analysis of protein interaction
networks found an enrichment of beta adrenergic recep-
tor molecules interacting with ANK3 and CACNA1C
[126], implicating both genes in modulation of adenylate
cyclase levels via catecholamine binding to beta adrenergic
receptors. Adenylate cyclase not only regulates cAMP
levels that are important in many intracellular signaling
pathways having various cellular effects, but calcium-
sensitive adenylate cyclases also enable faster reaction to
calcium influx that modulates neuronal excitability. Simi-
larly, the well-documented functions of ankyrin G in local-
izing inhibitory GABAergic interneuron synapses to the
AIS of excitatory neurons, as well as mediating activity-
dependent AIS relocation along axons, further supports a
common mechanism of ANK3 and CACNA1C in regula-
tion of neuronal excitability.
The CPG2 splice variant of SYNE1 functions in turn-
over of postsynaptic glutamate receptors on excitatory
neurons that is important for maintaining and modifying
synaptic strength [48]. Ankyrin G has a putative role in
synaptic stabilization based on the function of its Dros-
ophila homolog [74-76]. Perturbation of ankyrin G or
the CPG2 protein could potentially disrupt synaptic
transmission within and between neural circuits relevant
to BD, leading to the symptoms and cognitive deficits
exhibited by patients.
ANK3 and DGKH both appear to participate in intra-
cellular phosphatidylinositol signaling that mediates an
enormous diversity of cellular functions, which in the
brain include neural cell growth and proliferation, differ-
entiation, and neuroprotection. The ankyrin G isoforms
localized to late endosomes and lysosomes bind the p85
subunit of phosphatidylinositol 3’-kinase (PI3K) [73],
whose products activate Akt kinase to phosphorylate a
variety of protein targets with a range of cellular effects.
Diacylglyceraldehyde kinase eta, encoded by DGKH, cat-
alyzes the breakdown of diacylglycerol, which is an acti-
vator of protein kinase C that, like Akt, has a multitude
of targets with diverse effects. Thus, ANK3 and DGKH
may both help regulate key kinase proteins in this path-
way to modulate a variety of cellular functions. This link
between ANK3 and DGKH is particularly interesting as
the phosphatidylinositol pathway is a putative target of
the both lithium and valproate used in BD treatment
[25,87,88,127]. It is therefore possible that sequence var-
iants in ANK3 and DGKH alter the functions of their
encoded proteins in this pathway, disrupting down-
stream neural processes that lead to the emergence of
BD symptoms, and that mood stabilizers mediate their
clinical effect through normalizing pathway signaling.
A highly speculative link between the ANK3, NCAN,
and ODZ4 genes is formation of a complex that mediates
neuronal migration and axon pathfinding. The neurocan
and tenascin-M4 proteins encoded by NCAN and ODZ4,
respectively, are both cell surface proteins expressed in
brain that are implicated in these neuronal processes.
Given the core function of ankyrin G in coupling integral
membrane proteins to the inner membrane cytoskeleton
[62,63], ankyrin G may hold tenascin-M4 at the cell sur-
face by binding to the tenascin-M4 intracellular domain.
In turn, tenascin-M4 could interact with neurocan on the
cell surface, as suggested by the direct binding of
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[128]. Additional evidence for a putative role of ankyrin G
in axon pathfinding comes from studies of the ankyrin
homolog in the nematode C. elegans, unc-44, which is
required for proper axon projection to targets [129,130].
Widespread perturbation of axon pathfinding would have
global effects on brain function. However, if localized to
neural circuits relevant to BD, for example by restricted
expression of BD associated genes that mediate pathfind-
ing, the consequence could be a distinct dysregulation of
mood and cognition.
Conclusions
Recent GWAS of BD have provided solid evidence for a
handful of genetic risk factors that suggest biological
pathways underlying BD and potential new treatment
targets, among which ANK3 is one of the strongest and
most replicated genes. The ankyrin G protein encoded
by ANK3 functions as a scaffold protein and adapter
molecule between various membrane proteins and the
inner membrane cytoskeleton. In the brain, the best
characterized functions of ankyrin G include formation
and maintenance of the AIS and Nodes of Ranvier,
which mediate action potential firing and propagation,
and modulation of neuronal excitability. In individuals
with BD, altered ankyrin G function in these processes
could perturb the proper development and function of
neural circuits that regulate mood. Although less stud-
ied, ankyrin G is also implicated in adult neurogenesis,
synaptic transmission, protein trafficking, and intracellu-
lar signaling. Involvement of ANK3 in biological pro-
cesses that are shared with other GWAS genes allows
speculation about specific BD disease mechanisms, in-
cluding calcium-mediated neuronal excitability, synaptic
transmission, intracellular signaling, neuronal migration,
and axonal pathfinding. Functional studies of ANK3 and
other BD risk genes in human populations, as well as
animal and cellular models, will be important to eluci-
date the mechanism by which ANK3 exerts its effect on
BD susceptibility.
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